Navigation Links
Sundance Diagnostics Developing Antidepressant Suicide Risk Test
Date:12/12/2013

BOULDER, Colo., Dec. 12, 2013 /PRNewswire/ -- Sundance Diagnostics announces they have entered into an exclusive, worldwide licensing agreement with the Max Planck Institute of Psychiatry, Munich, Germany, to expand the Institute's initial clinical validation of genetic markers and to commercialize a genetic test that predicts risk of suicide emerging from use of antidepressant drugs. 

(Photo: http://photos.prnewswire.com/prnh/20131212/AQ32409)

The test is to enable physicians to decrease the risk of suicide in patients treated with single antidepressant drugs and combinations of psychiatric medications. 

According to IMS Health, there are over 9 million new patient prescriptions written each year in the U.S.  An additional 9 million new patient prescriptions are estimated to be written yearly worldwide. 

The company is preparing for the launch of the test as a laboratory developed test in the United States and Europe and will announce in early 2014 when it will be available.  In addition, clinical studies will be initiated in support of a U.S. Food and Drug Administration submission for market clearance, European CE marking and insurance reimbursement.  The company plans for applications to be submitted to the regulatory agencies within 18 months.

The Max Planck scientific team was led by Andreas Menke, M.D. and Elisabeth Binder, M.D. Ph.D.  The scientists discovered 79 genetic markers that had a 91% probability of correctly classifying patients at risk of antidepressant-induced suicide in an independent replication study. 

Of the 8.1% of patients who developed antidepressant-induced suicidality in the Institute's study, nearly 60% experienced the serious side effect within two weeks of beginning treatment.

Contrary to the current FDA warning that persons under the age of 25 have the greatest risk, study results indicated there was no age difference between those who developed suicidal ideation and those who did not.  Scientists at the National Institute of Mental Health (NIMH), in their 1,900-patient STAR*D study, showed similar data.  

Since 2005 all antidepressant drugs in the U.S., Canada and a number of European countries have carried the highest level warning for risk of suicide, but doctors have not been able to determine which patients may be at risk – sometimes with tragic results. 

Sundance CEO Kim Bechthold stated, "Our hope is that the new test will assist the physician in significantly reducing the risk of these tragic results and will provide patients and families with valuable personal information to use with their doctors in planning treatment."

Eleven percent of Americans age 12 and over are reported to be taking an antidepressant drug in the CDC's National Health and Nutrition Examination Survey (NHANES).  Antidepressant use increased 400% from the period 1988-1994 through 2005-2008, according to the National Center for Health Statistics. 

The original research, "Genome-Wide Association Study of Antidepressant Treatment-Emergent Suicidal Ideation," was published online in Neuropsychopharmacology  October 26, 2011. 

The licensing agreement was concluded with Max Planck Innovation, the Max Planck Institute´s technology transfer organization.

Sundance Diagnostics' Chief Scientific Advisor is Peter Tolias, Ph.D., Professor and Director of the Stevens Institute of Technology, Center for Healthcare Innovation in Hoboken, New Jersey. 

About Sundance Diagnostics

Sundance Diagnostics, based in Boulder, Colorado, is a diagnostic test developer focusing on genetic companion diagnostic tests to reduce the risk of serious side effects from major-market pharmaceutical medications.  The company has assembled a group of leading scientific and medical experts in genetics, molecular diagnostics, psychiatry and neuropsychopharmacology.

About the Max Planck Institute of Psychiatry

The Max Planck Institute of Psychiatry in a unique way combines basic research, clinical research and patient care in the field of psychiatry and neurology. The main focus of research and clinical treatment options lies on depression and anxiety disorders. In the field of psychiatry, the Max Planck Institute of Psychiatry is regarded as one of the world-wide leading research institutes concentrating on the development of personalized medicine.

Press release contact:

Kim Bechthold,
CEO, Sundance Diagnostics
Phone: 303 862-2770 
kbech@sundancedx.com

Max Planck Institute of Psychiatry contacts:

Dr. Dr. Elisabeth Binder
Managing Director, Max Planck Institute of Psychiatry, Department of Translational Research in Psychiatry and Stress-related Disorders  
Phone: 49 89 30622-1
binder@mpipsykl.mpg.de

Dr. Andreas Menke
Scientist and Resident, Max Planck Institute of Psychiatry, Department of Translational Research in Psychiatry and Stress-related Disorders  
Phone: 49 89 30622-1
menke@mpipsykl.mpg.de                                      


'/>"/>
SOURCE Sundance Diagnostics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sundance Channels Push Girls star, Chelsie Hill, Leads Line Up of New Products, Services and Technology at Abilities Expo-The Nations Leading Expo for People with Disabilities on June 28-30
2. QBC Diagnostics Awarded GSA Contract
3. Quest Diagnostics Establishes Unique Healthcare Identifier to Improve Access to Vital Patient Health Information; 80 Million Patient IDs Created to Date
4. Heightened Awareness, Coupled with Expanding Patient Pool, Stimulates Sleep Apnea Diagnostics and Sleep Services Market, Says Frost & Sullivan
5. Ariosa Diagnostics to Present and Exhibit at the 16th International Conference on Prenatal Diagnosis and Therapy
6. ZINO Society Targets Medical Devices, Healthcare IT and Diagnostics
7. Quest Diagnostics To Speak At The Wells Fargo Securities 2012 Healthcare Conference
8. Breakthrough Prostate Cancer Diagnostics
9. NicOx Signs Worldwide Licensing Agreement With Rapid Pathogen Screening, Inc. For Ophthalmic Diagnostics
10. Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets
11. QIAGEN Unveils Initiative to Create Next-Generation Sequencing Portfolio for use in Clinical Research and Molecular Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... Sept. 18, 2017 EpiVax, Inc. ... bioinformatics and immune engineering, today announced a ... A (H7N9) vaccine. ... seasonal influenza and presents a challenge for ... exposure to be effective. Using state-of-the-art bioinformatics and ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , the ... chains, has published the first annual edition of its Global CSR Risk ... 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly ... ... Performance Index ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., ... Solutions (VLMS), is pleased to announce the appointment ... member of its Board of Directors and Chairman ... VLMS enables life science companies to manage their ... use of paper in this process. Furthermore, ValGenesis ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) ... a collection of specialty vendors and unique items from across the nation, this holiday-themed ... and wellness services offered by the VNA. The boutique will be open Saturday, ...
(Date:10/13/2017)... ... 13, 2017 , ... Talented host, actor Rob Lowe, is ... a new episode of "Success Files," which is an award-winning educational program broadcasted ... each subject in-depth with passion and integrity. , Sciatica occurs when the sciatic ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), an ... showcase a range of technology and learning solutions at the 68th Annual American ... to be held October 14–18, 2017 at the Mandalay Bay Resort in Las ...
(Date:10/12/2017)... PALM CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... of cold therapy products, announced today the introduction of an innovative new design of ... the multipurpose pad so you get maximum comfort while controlling your pain while using ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... has recently contributed a medical article to the newly revamped Cosmetic Town ... article spotlights the hair transplant procedure known as Follicular Unit Extraction ...
Breaking Medicine News(10 mins):